Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00706030 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
A Phase 1 study of Breast Cancer and Advanced Malignant Solid Tumors, sponsored by Puma Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
- 20
- Study locations
NCT00706030 is a Phase 1 study of Breast Cancer and Advanced Malignant Solid Tumors that has completed, run by Puma Biotechnology. The registered enrollment target is 92 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT00706030, a Phase 1 study of Breast Cancer and Advanced Malignant Solid Tumors, has completed, sponsored by Puma Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to identify the highest tolerable dose of neratinib (HKI-272) in combination with vinorelbine and to assess the safety of the combination of the two drugs as well as to obtain preliminary information on whether the combination of the two drugs has any effect on solid tumors. The study will be conducted in two parts. In the first part, testing will be done on up to 12 subjects to determine the highest tolerable dose of HKI-272 and vinorelbine in patients with advanced solid tumors. In the second part of the study, approximately 60 additional subjects with metastatic ErbB-2-positive breast cancer, with no prior exposure to lapatinib, are planned to be added to better define the tolerability and preliminary activity of HKI-272 in combination with vinorelbine. Up to 20 additional subjects with ErbB-2-positive breast cancer with prior lapatinib exposure are also planned to be enrolled in part 2 for exploratory analyses.
Conditions Studied
Interventions
- DRUG vinorelbine
- DRUG neratinib
Study Locations (20)
Other
- AZ Klina Brasschaat - Brasschaat
- Institut Jules Bordet - Brussels
- St.-Augustinus Hospital Oncology Department - Wilrijk
- Centre Paul Papin - Angers
- Institut Paoli Calmette - Marseille
- Institut Curie, Département d'Oncologie Médicale - Paris
- Institut Claudius Regaud - Toulouse
- Queen Mary Hospital - Hong Kong
New York
- Columbia University Medical Center - New York
- Hematology Oncology Associates of Rockland - Nyack
- Albert Einstein Cancer Center - The Bronx
Beijing Municipality
- Cancer Hospital, Chinese Academy of Medical Sciences - Beijing
- The Hospital Affiliated Academy Military Medical Science, Chinese People's Liberation Army - Beijing
- Chinese People's Liberation Army General Hospital - Beijing
Arkansas
- Highlands Oncology Group - Fayetteville
California
- City of Hope National Medical Center - Duarte
New Hampshire
- Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center - Lebanon
North Carolina
- Carolinas Hematology-Oncology Associates - Charlotte
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2008-04-29 |
| Est. Completion | 2018-06-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00706030
The ClinicalTrials.gov registry entry for NCT00706030 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Puma Biotechnology, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which vinorelbine is the first listed.
NCT00706030 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, New York, Beijing Municipality.
Frequently Asked Questions
What is clinical trial NCT00706030 about?
NCT00706030 is a clinical study titled "Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer". The purpose of this study is to identify the highest tolerable dose of neratinib (HKI-272) in combination with vinorelbine and to assess the safety of the combination of the two drugs as well as to obtain preliminary information on whether the combination of the two drugs has any effect on solid tum...
What is the current status of trial NCT00706030?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2008-04-29. Estimated completion is 2018-06-07.
What conditions does trial NCT00706030 study?
This clinical trial studies the following conditions: Breast Cancer, Advanced Malignant Solid Tumors.
What interventions are being tested in trial NCT00706030?
The interventions under investigation include: vinorelbine (DRUG), neratinib (DRUG).
Who is sponsoring clinical trial NCT00706030?
This trial is sponsored by Puma Biotechnology, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00706030 being conducted?
This trial has 20 study locations across Arkansas, California, New Hampshire, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.